← All drugs built on NIH-funded research

You paid twice

Aphelion: public research in, public money out

Aphelion sells one drug protected by patents that were reported to NIH as inventions made with NIH grants. The figures below sit side by side; we do not claim that lobbying or donations set any price.

Medicare paid, 2024

—

for these drugs, before rebates

Medicaid paid, 2024

—

before rebates

NIH grants behind the patents

$15M

6 grants, whole-grant totals

Federal lobbying

—

not among the clients we track yet

Aphelion's drugs on this list

DrugCompanyResearch reported byNIH grantsMedicare 2024Medicaid 2024
Pylarify Truvu

Piflufolastat F-18

AphelionJohns Hopkins University$15M——

How this is built. Universities and companies that use NIH grants must report the inventions those grants produce to NIH, under the Bayh-Dole Act. NIH publishes the patent numbers and the grants they were reported under. We match those patents to the patents drug makers list with the FDA for each approved drug (the Orange Book), then add what Medicare Part D, Part B and Medicaid paid for each drug. Only patents still listed with the FDA appear, so drugs whose patents have expired drop out, and biologics, which the Orange Book does not cover, are not here yet.

What the numbers mean. "NIH grants" is everything NIH paid out on the grants a patent was reported under, from 1985 on. A grant usually paid for more than the one invention, so it is not the cost of the drug. Medicare and Medicaid figures are gross spending before the rebates drug makers pay back, which are confidential. Companies also paid for the clinical trials that took these drugs to approval; each drug page links the company's own filings.

Sources: NIH RePORTER patents reported under NIH grants (from iEdison); NIH RePORTER project funding; FDA Orange Book patent and product files; Medicare Part D Spending by Drug; Medicare Part B Spending by Drug; Medicaid Spending by Drug. Updated 2026-11-05.